Allergan, Alcon Settle Patent Feud Over Eye Drops

Law360, New York (March 9, 2006, 12:00 AM EST) -- Botox manufacturer Allergan Inc. and Alcon Inc. have amicably ended a patent infringement battle that has lasted nearly two years over Alcon’s brimonidine 0.15% eye drops product.

Earlier this week, U.S. District Judge Gregory M. Sleet dismissed the case with prejudice, with each party to bear its own costs and attorneys’ fees.

Under the terms of the settlement, Alcon has agreed to a license beginning on Sept. 30, 2009 in the U.S. under both patents at issue in the suit. In addition, Alcon will not sell,...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.